Background. Osteoporosis is a common complication of long-term glucocorticoid therapy for which
Glucocorticoid induced bone loss is now a well reon glucocorticoids. There is a wide variety of advice available 10 12 14-19 but uncertainty remains about the precognised clinical problem. 1 It may lead to osteoporotic fractures 2 and occurs in patients being treated with cise way forward. [20] [21] [22] Osteoporosis is defined as a progressive systemic glucocorticoids for different conditions such as rheumatoid arthritis, 3 asthma, 4 and polymyalgia rheumatica. skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue with a Rapid bone loss may occur during the first year of treatment 6 and there is justified concern about the consequent increase in bone fragility and susceptibility to fracture. 7 In the UK osteoporosis results in over need for preventative strategies for patients starting on glucocorticoid treatment so that osteoporosis does not 200 000 fractures each year, at an annual cost to the National Health Service of over £940 million, and more occur. However, the increased awareness of the need to diagnose and prevent osteoporosis in general, 7 8 the than one third of adult women will sustain one or more osteoporotic fractures in their lifetime. 7 Strategies for complex pathogenesis of steroid induced bone loss, 9 the limited evidence to support current strategies for the the prevention and identification of risk factors for osteoporosis are therefore important so that the burden prevention of steroid bone loss, 10 11 and the pharmaceutical zeal to produce new agents and new apof osteoporotic fractures can be reduced. Much attention has focused on risk factor frequency so that plications of present ones 12 13 has led to a confused atmosphere for the practising clinician treating patients subjects at high risk of osteoporosis can be targeted for bone mass measurements and preventive treatment. for many years (>10 mg prednisolone per day) bone The use of risk factor questionnaires has been limited loss is most rapid soon after starting treatment and in their success in identifying patients likely to develop occurs to a similar extent from the proximal femur and fractures. However, it is now recognised that certain the lumbar spine. 6 A recent cross sectional study in risk factors are more useful predictors of fracture than general practice in Nottinghamshire was undertaken to others. 23 These are reduced bone mineral density, history determine the prevalence of continuous use of oral of a prior fracture after the age of 40 years, history of steroids in the general population and the extent to a fracture at the hip, wrist or vertebra in a first degree which patients taking oral steroids were taking treatment relative (family history), being in the lowest quartile to prevent osteoporosis. 34 Three hundred and three in weight (≤57.8 kg, thinness), and current cigarette patients were currently taking "continuous" oral glucosmoking. Bone mass is accurately assessed by measurecorticoid treatment, representing 0.5% of the total ments of bone mineral density. A working group of the population studied. The usual steroid prescribed was World Health Organisation has defined osteoporosis as prednisolone (97%) and the mean dose was 8.0 mg/ a bone mineral density that is 2.5 SD below the mean day. Nineteen per cent of the patients were receiving peak value in young adults. 24 This is known as the prednisolone for asthma and chronic obstructive airways T score. Lesser degrees of bone loss are defined as disease. Only 14% (41) of the overall group of 303 osteopenia (T score between 2.5 SD and 1 SD below patients had received treatment for the prevention of the mean peak value in young adults). These limits are osteoporosis. It is suggested that there may be at least useful in making a diagnosis and also in assessing which 250 000 people in the UK taking continuous oral sterpatients are at risk. 25 Bone density is widely measured oids who need prophylaxis against osteoporosis. by dual energy x ray absorptiometry (DXA) 26 of the However, in respiratory medicine many patients relumbar spine (particularly trabecular bone) and of the ceive inhaled steroids, often with intermittent courses femoral neck (predominantly cortical bone). However, of oral prednisolone. There is concern about the effect other methods involving assessment of the appendicular of this type of treatment and its potential for putting skeleton (peripheral DXA (pDXA) and ultrasound patients at risk of osteoporosis. 35 The evidence from measurements of the calcaneus) are being developed published studies has been confusing, partly because for use in clinics and health centres. 26 biochemical bone cell markers have been used at the Bone remodelling is a complex process involving end point as well as bone density. Even though inhaled a number of cellular functions directed towards the beclomethasone at a dose of 2000 g/day produces a coordinated resorption and formation of new bone. A significant decline in serum osteocalcin after nine weeks sequence of events is initiated by local events so that of treatment, 36 and there is a decline in bone density in osteoclastic activity produces bone resorption. This is patients taking inhaled steroids only at more usual lower followed by attraction, proliferation, and differentiadoses, 37 there is little evidence that long term treatment tion of osteoblast cells which lay down new bone and with inhaled steroids is associated with an increased risk repair the resorption defects caused by resorbing of osteoporotic fractures. [38] [39] [40] It seems that it is a high osteoclasts.
27 28 The end point of bone remodelling is daily dose of inhaled steroids, rather than the duration the maintenance of the bone mass. It is governed by of the dose, that may adversely affect bone density. A systemic hormones and local factors including glucomparison of the effect of fluticasone and budesonide cocorticoid and sex steroids. Bone loss may occur if the on bone markers and bone density during one year of bone resorbed is not fully replaced due to overactivity treatment did not show a decrease in bone density.
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of the osteoclast or underactivity of the osteoblast. The Glucocorticoids produce bone loss by means of direct functions of osteoblasts and osteoclasts may be assessed and indirect effects on bone. 17 Histomorphometric studby biochemical bone cell markers such as serum bone ies 42 indicate that glucocorticoids depress osteoblast specific alkaline phosphatase, osteocalcin, and type I function. In patients treated with glucocorticoids there procollagen peptides (bone formation) and serum or is a greater than normal deficit in the quantity of bone urine pyridinoline crosslinks (bone resorption). 29 replaced in each remodelling cycle. This leads to an enhanced rate of bone loss, which is more severe in parts of the skeleton with a high proportion of cancellous Extent of the problem bone such as the vertebrae and ribs, where fractures It is generally accepted that moderate to high dose frequently occur. The low osteoblast activity is conglucocorticoid therapy is associated with loss of bone firmed by reduced osteocalcin levels in glucocorticoid and increased risk of fracture. 15 Some experts believe dependent asthmatic patients. 43 The possible reversthat at doses of more than 10 mg prednisolone orally ibility of the effects of glucocorticoids on the osteoblast per day, all patients lose significant amounts of bone. 17 is important from the clinical point of view. There is This is not necessarily so as some Caucasian and Afroevidence from patients treated for Cushing's syndrome Caribbean patients often seem to be protected from that the deleterious effects of glucocorticoids on the bone loss and osteoporosis, even when receiving high skeleton are reversible. 44 45 However, in practice if loss doses of oral glucocorticoids. Also, not all postof trabecular plates and microfractures has occurred menopausal women on chronic steroid and oestrogen within the bone, it is unlikely that a significant reversal treatment are osteoporotic 30 and, in some instances, the of the effect can be expected on withdrawal of glucoglucocorticoid induced bone loss is superimposed on corticoid treatment. bone loss which is already increased because of the In addition, there are important indirect effects of underlying disease process. Inflammation in polyglucocorticoids on bone. 17 These include a generalised myalgia rheumatica increases bone resorption and apdefect in calcium transport, secondary hyperpears to have a more detrimental effect on bone than parathyroidism, and deficiency of anabolic hormones the glucocorticoid treatment. 31 This disorder is (table 1) . As a result there is impaired gastrointestinal associated with high levels of cytokines such as interabsorption of calcium, hypercalciuria, secondary hyperleukin 6 32 which is known to stimulate osteoclast parathyroidism, deficiency of oestrogen and tesformation and prevents osteoclast apoptosis. 33 Nevertheless, in many patients given high dose corticosteroids tosterone, as well as the direct effects on bone turnover. The duration of glucocorticoid therapy did not have any effect on the response to treatment, nor apparently In order to prevent the skeletal side effects of glucocorticoid treatment there is much interest in developing did the underlying disease state. However, there is concern about the minimal loss of lumbar spine bone strategies for use in clinical practice. The bisphosphonate drugs have been widely used as agents to mass in the patients in the placebo group, as would be expected in response to glucocorticoids. This suggests prevent bone resorption 46 and the paper by Saag and colleagues 13 for the Glucocorticoid Induced Osteothat the effect of alendronate in preventing bone loss may not have been very robustly tested in some patients. porosis Interventional Study Group reports the results of a randomised placebo controlled study of the amino
In the subgroup of patients with bullous skin diseases who were receiving high daily doses of glucocorticoids bisphosphonate alendronate in 477 patients who were receiving glucocorticoid therapy. The patients studied (mean dose 23.5 mg prednisolone or equivalent) lumbar spine bone density in the patients in the placebo group were men and women of a wide age range (18-83 years) who were receiving their treatment for a variety of decreased by 3% while in those treated with alendronate it increased by 2% from baseline, giving a total difference different disorders of which only up to 10% were for respiratory disorders. The multicentre study was conof 5%. Biochemical bone markers of bone turnover, bone formation, and bone resorption are known to ducted in two parts in parallel, one involving 232 patients at 15 centres in the USA and the other involving decrease in response to alendronate treatment in postmenopausal women. 50 51 Also, bone turnover is increased 328 patients at 22 centres in 15 other countries. The patients enrolled were receiving at least 7.5 mg predin postmenopausal patients with osteoporosis. 52 The effect of glucocorticoids on bone suppresses bone turnnisolone or equivalent for different lengths of time (<4 months to >12 months) and were included in the over, 10 especially by suppressing osteoblast activity. Approximately 50% of the patients treated with alenstudy irrespective of baseline bone mineral density. The patients were randomly assigned to receive placebo or dronate in the study by Saag et al underwent bone marker measurements. The type of patients (sex and 5 mg or 10 mg alendronate. The treatment lasted for less than a year (48 weeks) and all patients received postmenopausal status) is not revealed. However, the response curves are related to reference values for precalcium and vitamin D supplements daily. There were a significant number of exclusion criteria but, of the menopausal women. There is evidence of increased bone resorption (urinary N telopeptides of type I col-232 postmenopausal women included (49%), 34% were taking oestrogen replacement. One hundred and forty lagen) at baseline and in the placebo group. However, the bone formation marker (serum bone specific alkaline one men (29.5%) were included in the study. The biochemical bone markers measured at the beginning phosphatase) is within the reference range at baseline and was not suppressed, as might have been expected. of the study were within the reference range. In particular, the bone alkaline phosphatase (bALP) was not In addition, the placebo values throughout the study did not decrease in response to glucocorticoid therapy. reduced as might be expected in response to glucocorticoid treatment. Unfortunately this study was not Serum osteocalcin (another bone formation marker used as an indicator of osteoblast activity) is known to destatistically powered to show the effect of alendronate on prevention of fractures.
crease in concentration following beclomethasone treatment in postmenopausal asthmatic women. 36 It is This paper describes an international collaboration to study the use of alendronate for the prevention possible that, although bone specific alkaline phosphatase and osteocalcin are both osteoblast markers, and treatment of glucocorticoid induced osteoporosis. Alendronate is known to be a very effective agent for they may represent markers of different stages of osteoblast function 53 and therefore respond to specific actions the prevention 47 and treatment of osteoporotic fractures 48 49 so studies of the use of alendronate in of glucocorticoids on the osteoblast. glucocorticoid bone loss have therefore been eagerly awaited. There was an increase in mean lumbar spine bone density of 2.1% and 2.9% in response to doses of    Intermittent treatment with etidronate has been shown 5 mg and 10 mg alendronate, respectively (p<0.001).
The corresponding values for the placebo group showed to prevent corticosteroid induced bone loss in the lumbar spine. [54] [55] [56] No change in bone density occurred a decrease of 0.4%. The increases in the femoral neck bone density were less remarkable and the biochemical compared with placebo in the femoral neck and, when group.bmj.com on June 22, 2017 -Published by http://thorax.bmj.com/ Downloaded from patients were treated with etidronate, bone loss at the Strategy for management How therefore should we manage our patients who are lumbar spine was prevented. 54 56 Previous information starting glucocorticoid treatment for respiratory disease? on the use of alendronate in glucocorticoid treated
Before we can devise a strategy and consider the need patients is very limited. In patients with sarcoidosis 5 mg for prophylactic treatment there are many variables that alendronate prevented radial bone loss of 4.5% in 12 need to be recognised. For instance, is the patient at months. 57 The improvement in bone density docurisk of osteoporosis anyway because, for example, of a mented in these studies occurred within one year of family history of hip fracture? Does the patient already treatment and it is possible that these changes may be have undetected bone loss before the start of glucorelated to bone remodelling transient. 58 It is therefore corticoid treatment? Is the disease itself likely to cause important that much longer studies assessing the effect bone loss because of bone resorption secondary to of bisphosphonates on glucocorticoid bone loss are cytokines? Bone loss may occur very quickly in response undertaken.
to glucocorticoid treatment, or it may not occur at all. The structure-activity relationships of bisphosAt present we do not have the means to detect which phonates and the subtle differences between the moresponse is likely in a patient. Some ethnic groups may lecular mechanisms of action of etidronate and be more likely to develop steroid induced osteoporosis alendronate may be of interest when assessing the use than others. If we use the drugs at present licensed for of the drugs in preventing glucocorticoid induced bone osteoporosis treatment such as hormone replacement loss. In vitro studies have shown alendronate to be or bisphosphonates, how long should the treatment last? significantly more potent than etidronate 46 and, in postWill it give side effects? How should we monitor the menopausal osteoporosis, alendronate produces a greater increase in lumbar spine bone density than etidronate after three years of treatment. 48 59 The limited data available on alendronate and etidronate do not
All patients starting oral corticosteroids show any evidence of difference in potency between therapy for 3 months or longer including these bisphosphonates when used to treat glucocorticoid patients on inhaled steroid if at a high dose induced bone loss. Bisphosphonates are pyrophosphate should: analogues with a strong affinity for mineralised tissues A. Be advised about lifestyle measures to and are potent inhibitors of bone resorption. 46 These prevent bone loss. compounds have a P-C-P backbone structure. The B. Have a bone density measurement of the phosphorus atoms are linked to a geminal carbon having lumbar spine and femoral neck at the sites for two other groups (described as R 1 and R 2 ) beginning of treatment. which have enabled development of different analogues C. Be assessed for risk factors for osteoporosis (questionnaire) and have simple with different anti-bone resorptive potencies. The R 1 pathology tests to detect pre-existing risk site is termed the head or hook and is the predominant factors for osteoporosis (LFTs, creatinine and determinant for hydroxyapatite binding. The R 2 site is electrolytes, bone profile, TSH, FBC and ESR termed the bone tail or bioactive moiety and is chemtestosterone (in men)). ically modified to produce different compounds. 60 In etidronate the R 2 is a methyl group (CH 3 ) and in A. Important life style measures to aid alendronate the R 2 has a three-carbon side chain with prevention of osteoporosis: a terminal amino group ((CH 2 ) 3 NH 2 ). 61 The increased 1. Maintain adequate dietary calcium and side chain increases lipophilicity which may permit betvitamin D intake (1500 mg calcium and ter access to cell compartments. Also, the presence of 400 IU vitamin D per day). an amino group in the side chain gives a many hundred 2. Moderate alcohol intake. times increase in inhibition of bone resorption in potency 3. Reduce cigarette smoking. in vitro. with other types of bone loss.
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